Literature DB >> 11389490

Treatment of patients with refractory giardiasis.

T E Nash1, C A Ohl, E Thomas, G Subramanian, P Keiser, T A Moore.   

Abstract

Giardia lamblia is one of the most common parasitic infections. Although standard treatments are usually curative, some immunocompromised patients, including patients with acquired immunodeficiency syndrome as well as healthy patients, have giardiasis that is refractory to recommended regimens. We report our experience with 6 patients with giardiasis, for whom therapy with a combination of quinacrine and metronidazole resulted in cures for 5 of the 6 patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389490     DOI: 10.1086/320886

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  25 in total

Review 1.  Current drug therapy of protozoal diarrhoea.

Authors:  Y K Gupta; Madhur Gupta; S Aneja; K Kohli
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

Review 2.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Comparison of Cytokine Responses in Ecuadorian Children Infected with Giardia, Ascaris, or Both Parasites.

Authors:  Jill Weatherhead; Andrea Arévalo Cortés; Carlos Sandoval; Maritza Vaca; Martha Chico; Sophia Loor; Philip J Cooper; Rojelio Mejia
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

4.  Short course combination therapy for giardiasis after nitroimidazole failure.

Authors:  Rogelio Lopez-Velez; Carolina Batlle; Carolina Jiménez; Miriam Navarro; Francesca Norman; Jose Perez-Molina
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 6.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

7.  Impaired parasite attachment as fitness cost of metronidazole resistance in Giardia lamblia.

Authors:  Noa Tejman-Yarden; Maya Millman; Tineke Lauwaet; Barbara J Davids; Frances D Gillin; Linda Dunn; Jacqueline A Upcroft; Yukiko Miyamoto; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

8.  Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children.

Authors:  Roberto Canete; Angel A Escobedo; Maria E Gonzalez; Pedro Almirall
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

9.  Inhibition of Kir4.1 potassium channels by quinacrine.

Authors:  Leticia G Marmolejo-Murillo; Iván A Aréchiga-Figueroa; Meng Cui; Eloy G Moreno-Galindo; Ricardo A Navarro-Polanco; José A Sánchez-Chapula; Tania Ferrer; Aldo A Rodríguez-Menchaca
Journal:  Brain Res       Date:  2017-03-11       Impact factor: 3.252

10.  Unraveling how Giardia infections cause disease.

Authors:  Theodore E Nash
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.